NKTR
NEKTAR THERAPEUTICS · Healthcare · Market cap $1.3B
Insiders sold $441K net in the last 90 days ·2 sellers, 0 buyers· 1 of 3 sales under Rule 10b5-1 plans· latest Form 4 filed Aug 20, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.4M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Sep 26, 2026
Zalevsky Jonathan
NEKTAR THERAPEUTICS (NKTR) has 20 SEC Form 4 filings (26 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Sep 26, 2026.
Inside the rolling window, 3 insiders at NEKTAR THERAPEUTICS reported no open-market purchases and 14 open-market sales totaling $2.4M. The most active filer is Chief R&D Officer Zalevsky Jonathan with 7 filings. Insiders have net sold $2.0M over the trailing 6 months. The most recent open-market filing is a sale of 186 shares by Chief R&D Officer Zalevsky Jonathan, dated Aug 18, 2026, worth $13K.
- Industry:Biotechnology
- CEO:Howard W. Robin
- Employees:63
- HQ:San Francisco, CA, US
- IPO:1994-05-03
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief R&D Officer | Sale | 186 | $13K | Aug 20 | -48.1% | SEC ↗ | |
| President & CEO | Sale | 418 | $30K | Aug 20 | -48.1% | SEC ↗ | |
| Chief R&D Officer | Sale | 5,681 | $398K | Jul 2 | -45.6% | SEC ↗ | |
| President & CEO | Sale | 10,000 | $603K | Jun 18 | -36.6% | SEC ↗ | |
| President & CEO | Sale | 10,000 | $612K | Jun 18 | -36.6% | SEC ↗ | |
| Chief R&D Officer | Sale | 5,538 | $336K | Jun 17 | -36.6% | SEC ↗ | |
ROBIN HOWARD WFirst in 3 months | President & CEO | Sale | 444 | $29K | May 21 | -43.6% | SEC ↗ |
Zalevsky JonathanFirst in 3 months | Chief R&D Officer | Sale | 199 | $13K | May 21 | -43.6% | SEC ↗ |
| President & CEO | Sale | 423 | $31K | Feb 20 | — | SEC ↗ | |
| Chief R&D Officer | Sale | 180 | $13K | Feb 20 | — | SEC ↗ | |
| Chief R&D Officer | Sale | 3,867 | $138K | Jan 22 | — | SEC ↗ | |
Wilson Mark AndrewFirst filing | Chief Legal Officer | Sale | 630 | $34K | Nov 25 | — | SEC ↗ |
Zalevsky JonathanFirst filing | Chief R&D Officer | Sale | 1,157 | $63K | Nov 25 | — | SEC ↗ |
ROBIN HOWARD WFirst filing | President & CEO | Sale | 2,207 | $120K | Nov 25 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does NKTR have?
NEKTAR THERAPEUTICS (NKTR) has 20 SEC Form 4 filings (26 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Sep 26, 2026.
When was the most recent SEC Form 4 filing for NKTR?
The most recent Form 4 filing for NKTR on Tracefour is dated Sep 26, 2026.
Who is the most active insider at NKTR?
The most active SEC Form 4 filer at NKTR in the rolling window is Chief R&D Officer Zalevsky Jonathan, with 7 filings.
What is the net insider flow at NKTR over the last 6 months?
Over the trailing 180 days, insiders at NKTR have net sold $2.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at NKTR in the current window?
Inside the rolling window, insiders at NKTR bought $0 and sold $2.4M based on SEC Form 4 filings.
Can I get alerts for NKTR insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at NEKTAR THERAPEUTICS (NKTR). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
NEKTAR THERAPEUTICS is in the Healthcare sector.